Werner syndrome helicase (WRN) has emerged as a compelling and highly selective therapeutic target in oncology, particularly for cancers characterized by microsatellite instability-high (MSI-H) and deficient mismatch repair (dMMR).

Chromatography is to separate, identify, and quantify the components of complex mixtures. Whether analyzing small molecules, peptides, biologics, metabolites, or impurities, chromatography provides the resolution and sensitivity needed to support every stage of pharmaceutical research.

Where chemistry meets biology—quantifying drugs, decoding metabolism, and powering precision in drug development.

SDS PAGE, Western blots, thermal gravimetry and related analysis

Mass spectrometry (MS) uses mass-to-charge for precise identification, quantification, and structural elucidation of small to large molecules.

Use of Nuclear Magnetic Resonance (NMR) Spectroscopy for quantitative or qualitative analysis of small molecules

Instruments from UV to IR, absorbance and emission through fluorescence encompassing spectrophotometers to microscopy applied towards in vitro and in vivo techniques.

Therapeutics acting on and taking advantage of cellular pathways and mechanisms of diseases in order to minimize off-target toxicity.

Strategies focused on targeting specific biomolecule or biological areas of interest

Protein-Protein and DNA-Protein interactions

identifying API metabolites and related effects in vivo

Explores the biochemical and molecular mechanisms of toxicity, predictive in silico models, off-target profiling, and strategies for minimizing adverse effects during drug development.

Interface of chemistry and computational science to make sense of large and complex biological datasets. Transforming raw information—like DNA sequences, protein structures, gene expression profiles, and metabolic pathways—into insights to understand how living systems work

QSAR is a computational approach that links a molecule’s chemical structure to its biological activity using mathematical models. The core idea is simple: similar structures tend to produce similar biological effects, and these patterns can be used to predict how novel molecules will behave.

Designing an organic synthesis is the art and science of constructing complex molecules from simpler building blocks. In drug discovery, this process is essential for creating novel compounds, optimizing lead structures, and enabling scalable production of drug candidates.

Green chemistry in drug discovery emphasizes the design of synthetic routes that are safer, more sustainable, and environmentally responsible — without compromising efficiency or innovation. It’s about rethinking how we build molecules to reduce waste, energy use, and toxic byproducts.

Large molecule APIs, or biologics, represent a rapidly expanding class of therapeutics built from complex biological macromolecules rather than traditional small‑molecule chemistry. These include monoclonal antibodies, recombinant proteins, peptides, nucleic acid therapeutics, and engineered cell or gene therapies.

Understanding chemical reactions and their mechanisms is central to designing and optimizing drug candidates. This section explores how medicinal chemists use mechanistic insight to build molecules with precision, efficiency, and purpose.

Small molecule APIs (Active Pharmaceutical Ingredients) are the traditional backbone of modern medicine. These compounds — typically low‑molecular‑weight, synthetically accessible organic molecules — form the majority of approved drugs worldwide

Synthetic route is to plan and execute the step‑by‑step construction of molecules. It highlights the strategic decisions that shape how efficiently, safely, and sustainably a compound can be made — from early discovery through scale‑up.